These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3060940)

  • 1. Liposome-encapsulated amphotericin B: a promising new treatment for disseminated fungal infections.
    Wiebe VJ; DeGregorio MW
    Rev Infect Dis; 1988; 10(6):1097-101. PubMed ID: 3060940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of liposomal amphotericin B in the treatment of systemic fungal infections.
    Patterson TF; Andriole VT
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 2():S63-8. PubMed ID: 2693111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children.
    Tollemar J; Klingspor L; Ringdén O
    Clin Microbiol Infect; 2001; 7 Suppl 2():68-79. PubMed ID: 11525221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical study of amphotericin B in the treatment of invasive fungal infection in 111 hematological disorder patients with neutrocytopenia].
    Tong HY; Zhang FJ; Xiao F; Qian WB; Meng HT; Mai WY; Tong Y; Mao LP; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):472-5. PubMed ID: 19035181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer.
    Groll AH; Müller FM; Piscitelli SC; Walsh TJ
    Klin Padiatr; 1998; 210(4):264-73. PubMed ID: 9743964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voriconazole versus amphotericin B in cancer patients with neutropenia.
    Jørgensen KJ; Gøtzsche PC; Johansen HK
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004707. PubMed ID: 16437492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New methods for delivery of antifungal agents.
    Meunier F
    Rev Infect Dis; 1989; 11 Suppl 7():S1605-12. PubMed ID: 2690298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial.
    Boogaerts M; Winston DJ; Bow EJ; Garber G; Reboli AC; Schwarer AP; Novitzky N; Boehme A; Chwetzoff E; De Beule K;
    Ann Intern Med; 2001 Sep; 135(6):412-22. PubMed ID: 11560454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New aspects in treatment of systemic mycoses].
    Presterl E; Graninger W
    Wien Klin Wochenschr; 1998 Nov; 110(21):740-50. PubMed ID: 9871965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B.
    Lopez-Berestein G; Mehta R; Hopfer RL; Mills K; Kasi L; Mehta K; Fainstein V; Luna M; Hersh EM; Juliano R
    J Infect Dis; 1983 May; 147(5):939-45. PubMed ID: 6842027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of liposome-encapsulated amphotericin in artificial/prosthetic cardiac valves for therapy and prevention of fungal endocarditis.
    Ratna S WV
    Med Hypotheses; 1999 Dec; 53(6):486-7. PubMed ID: 10687888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis of Candida albicans infection in neutropenic mice with liposome-encapsulated amphotericin B.
    Lopez-Berestein G; Hopfer RL; Mehta R; Mehta K; Hersh EM; Juliano RL
    Antimicrob Agents Chemother; 1984 Mar; 25(3):366-7. PubMed ID: 6721469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New approaches to antifungal chemotherapy.
    Viviani MA; de Marie S; Graybill JR; Yamaguchi H; Anaissie E; Caillot D
    Med Mycol; 1998; 36 Suppl 1():194-206. PubMed ID: 9988508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerance of high doses of amphotericin B by infusion of a liposomal formulation in children with cancer.
    Emminger W; Graninger W; Emminger-Schmidmeier W; Zoubek A; Pillwein K; Susani M; Wasserer A; Gadner H
    Ann Hematol; 1994 Jan; 68(1):27-31. PubMed ID: 8110875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of lipid formulations of amphotericin B for systemic fungal infections.
    Leenders AC; de Marie S
    Leukemia; 1996 Oct; 10(10):1570-5. PubMed ID: 8847891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal amphotericin B for the treatment of severe fungal infection.
    Michaud D
    Dynamics; 2001; 12(1):17-21. PubMed ID: 11982230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of systemic fungal infections in older patients: achieving optimal outcomes.
    Kauffman CA; Hedderwick SA
    Drugs Aging; 2001; 18(5):313-23. PubMed ID: 11392440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B].
    Viscoli C; Castagnola E
    Recenti Prog Med; 1999 Oct; 90(10):545-57. PubMed ID: 10592741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of systemic fungal infections with liposomal amphotericin B.
    Lopez-Berestein G; Bodey GP; Fainstein V; Keating M; Frankel LS; Zeluff B; Gentry L; Mehta K
    Arch Intern Med; 1989 Nov; 149(11):2533-6. PubMed ID: 2818111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AmBisome targeting to fungal infections.
    Adler-Moore J
    Bone Marrow Transplant; 1994; 14 Suppl 5():S3-7. PubMed ID: 7703928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.